Hints and tips:
...Bristol-Myers Squibb’s largest institutional investor has said it will not back the company’s $90bn takeover of Celgene. Cue the fire drills at Morgan Stanley and JPMorgan, the lead advisers....
...The case (now called FCC v. Fox Television Stations et al) was appealed to the US Supreme Court, where it was debated on Tuesday....
...counterbid for ImClone last year in response to an offer from Bristol-Myers Squibb....
...Bristol Myers Squibb was a rare gainer, its shares lifting 1.7 per cent to $21.02 after the US Food and Drug Administration said analyses of its experimental diabetes drug showed it met the agency’s guidelines...
...“We felt it was in the best interest of Bristol-Myers Squibb shareholders not to raise our previous $62 a share, all- cash offer,’’ James Cornelius, Bristol-Myers chief executive said in a statement....
...A shareholder derivative action in the Delaware Court of Chancery: Seymour v. Samuels, et al....
...JT follows Bristol Myers Squibb, the US pharmaceutical group, which last week announced a $275m charge to write down illiquid securities with exposure to subprime mortgages....
International Edition